Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone

Human Molecular Genetics

Volumn 19, Issue 9, 2010, Pages 1741-1755

  Custer, Sara K ^a   Neumann, Manuela ^b   Lu, Hongbo ^c   Wright, Alexander C ^c   Taylor, J Paul ^a  

^a Hospital TN USA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P97; TAR DNA BINDING PROTEIN; VALOSIN CONTAINING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BEHAVIORAL RESEARCH; BONE; BONE RADIOGRAPHY; BRAIN; CELL VACUOLE; CONTROLLED STUDY; FEMUR; GENE EXPRESSION; GENE MUTATION; IN VITRO STUDY; INCLUSION BODY MYOPATHY ASSOCIATED WITH PAGET BONE DISEASE AND FRONTOTEMPORAL DEMENTIA; MUSCLE; MUSCLE WEAKNESS; MYOPATHY; NONHUMAN; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE; VERTEBRA;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BLOTTING, WESTERN; BRAIN; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MUSCLE, SKELETAL; MUTATION, MISSENSE; MYOSITIS, INCLUSION BODY; OSTEITIS DEFORMANS;

DROSOPHILA MELANOGASTER; MUS; MUS MUSCULUS; SACCHAROMYCES CEREVISIAE;

EID: 77952486387     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq050     Document Type: Article

References (56)

1. Kimonis, V.E., Kovach, M.J., Waggoner, B., Leal, S., Salam, A., Rimer, L., Davis, K., Khardori, R. and Gelber, D. (2000) Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet. Med., 2, 232-241.
2. Forman, M.S., Mackenzie, I.R., Cairns, N.J., Swanson, E., Boyer, P.J., Drachman, D.A., Jhaveri, B.S., Karlawish, J.H., Pestronk, A., Smith, T.W. et al. (2006) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J. Neuropathol. Exp. Neurol., 65, 571-581.
3. Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M.P. and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet., 36, 377-381.
4. Haubenberger, D., Bittner, R.E., Rauch-Shorny, S., Zimprich, F., Mannhalter, C., Wagner, L., Mineva, I., Vass, K., Auff, E. and Zimprich, A. (2005) Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology, 65, 1304-1305.
5. Gidaro, T., Modoni, A., Sabatelli, M., Tasca, G., Broccolini, A. and Mirabella, M. (2008) An Italian family with inclusion-body myopathy and 1754 Human Molecular Genetics, 2010, Vol. 19, No. 9 frontotemporal dementia due to mutation in the VCP gene. Muscle Nerve, 37, 111-114.
6. Bersano, A., Del Bo, R., Lamperti, C., Ghezzi, S., Fagiolari, G., Fortunato, F., Ballabio, E., Moggio, M., Candelise, L., Galimberti, D. et al. (2009) Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiol. Aging, 30, 752-758.
7. Viassolo, V., Previtali, S.C., Schiatti, E., Magnani, G., Minetti, C., Zara, F., Grasso, M., Dagna-Bricarelli, F. and Di Maria, E. (2008) Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin. Genet., 74, 54-60.
8. Djamshidian, A., Schaefer, J., Haubenberger, D., Stogmann, E., Zimprich, F., Auff, E. and Zimprich, A. (2009) A novel mutation in the VCP gene (G157R) in a German family with inclusion-body myopathy with Paget disease of bone and frontotemporal dementia. Muscle Nerve, 39, 389-391.
9. Muller, J.M., Deinhardt, K., Rosewell, I., Warren, G. and Shima, D.T. (2007) Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem. Biophys. Res. Commun., 354, 459-465.
10. Weihl, C.C., Pestronk, A. and Kimonis, V.E. (2009) Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul. Disord., 19, 308-315.
11. Kakizuka, A. (2008) Roles of VCP in human neurodegenerative disorders. Biochem. Soc. Trans., 36, 105-108.
12. Ju, J.S., Fuentealba, R.A., Miller, S.E., Jackson, E., Piwnica-Worms, D., Baloh, R.H. and Weihl, C.C. (2009) Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J. Cell. Biol., 187, 875-888.
13. Tresse, E., Salomons, F.A., Vesa, J., Bott, L.C., Kimonis, V., Yao, T.P., Dantuma, N.P. and Taylor, J.P. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy, 6, 217-227.
14. Guinto, J.B., Ritson, G.P., Taylor, J.P. and Forman, M.S. (2007) Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta. Neuropathol., 114, 55-61.
15. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
16. Weihl, C.C., Miller, S.E., Hanson, P.I. and Pestronk, A. (2007) Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum. Mol. Genet., 16, 919-928.
17. Kawai, M., Bessho, K., Kaihara, S., Sonobe, J., Oda, K., Iizuka, T. and Maruyama, H. (2003) Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Hum. Gene. Ther., 14, 1547-1556.
18. Ueno, N., Inui, A., Iwamoto, M., Kaga, T., Asakawa, A., Okita, M., Fujimiya, M., Nakajima, Y., Ohmoto, Y., Ohnaka, M. et al. (1999) Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology, 117, 1427-1432
19. Ray, P.S., Martin, J.L., Swanson, E.A., Otani, H., Dillmann, W.H. and Das, D.K. (2001) Transgene overexpression of alphaB crystallin confers simultaneous protection against cardiomyocyte apoptosis and necrosis during myocardial ischemia and reperfusion. FASEB. J., 15, 393-402
20. Bruijn, L.I., Becher, M.W., Lee, M.K., Anderson, K.L., Jenkins, N.A., Copeland, N.G., Sisodia, S.S., Rothstein, J.D., Borchelt, D.R., Price, D.L. et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 18, 327-338.
21. Reddy, P.H., Charles, V., Williams, M., Miller, G., Whetsell, W.O. Jr and Tagle, D.A. (1999) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 354, 1035-1045.
22. Kimonis, V.E., Mehta, S.G., Fulchiero, E.C., Thomasova, D., Pasquali, M., Boycott, K., Neilan, E.G., Kartashov, A., Forman, M.S., Tucker, S. et al. (2008) Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am. J. Med. Genet. A, 146A, 745-757.
23. Amato, A.A. and Barohn, R.J. (2009) Inclusion body myositis: old and new concepts. J. Neurol. Neurosurg. Psychiatry, 80, 1186-1193.
24. Broccolini, A., Gidaro, T., Morosetti, R. and Mirabella, M. (2009) Hereditary inclusion-body myopathy: clues on pathogenesis and possible therapy. Muscle Nerve, 40, 340-349.
25. Gitcho, M.A., Strider, J., Carter, D., Taylor-Reinwald, L., Forman, M.S., Goate, A.M. and Cairns, N.J. (2009) VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem., 284, 12384-12398.
26. Weihl, C.C., Temiz, P., Miller, S.E., Watts, G., Smith, C., Forman, M., Hanson, P.I., Kimonis, V. and Pestronk, A. (2008) TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol. Neurosurg. Psychiatry, 79, 1186-1189.
27. Kim, J., Lowe, T. and Hoppe, T. (2008) Protein quality control gets muscle into shape. Trends. Cell. Biol., 18, 264-272.
28. Wohlgemuth, S.L., Crawford, B.D. and Pilgrim, D.B. (2007) The myosin co-chaperone UNC-45 is required for skeletal and cardiac muscle function in zebrafish. Dev. Biol., 303, 483-492.
29. Janiesch, P.C., Kim, J., Mouysset, J., Barikbin, R., Lochmuller, H., Cassata, G., Krause, S. and Hoppe, T. (2007) The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to human myopathy. Nat. Cell. Biol., 9, 379-390.
30. Neumann, M., Mackenzie, I.R., Cairns, N.J., Boyer, P.J., Markesbery, W.R., Smith, C.D., Taylor, J.P., Kretzschmar, H.A., Kimonis, V.E. and Forman, M.S. (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol. Exp. Neurol., 66, 152-157.
31. Davidson, Y., Kelley, T., Mackenzie, I.R., Pickering-Brown, S., Du Plessis, D., Neary, D., Snowden, J.S. and Mann, D.M. (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta. Neuropathol., 113, 521-533.
32. Lalonde, R., Kim, H.D., Maxwell, J.A. and Fukuchi, K. (2005) Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci. Lett., 390, 87-92. 33.
33. Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P.C. et al. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci., 22, 9340-9351.
34. Tarantino, L.M., Gould, T.J., Druhan, J.P. and Bucan, M. (2000) Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mamm. Genome, 11, 555-564.
35. Geser, F., Brandmeir, N.J., Kwong, L.K., Martinez-Lage, M., Elman, L., McCluskey, L., Xie, S.X., Lee, V.M. and Trojanowski, J.Q. (2008) Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol., 65, 636-641.
36. Ittner, L.M., Fath, T., Ke, Y.D., Bi, M., van Eersel, J., Li, K.M., Gunning, P. and Gotz, J. (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. USA, 105, 15997-16002.
37. Sennvik, K., Boekhoorn, K., Lasrado, R., Terwel, D., Verhaeghe, S., Korr, H., Schmitz, C., Tomiyama, T., Mori, H., Krugers, H. et al. (2007) Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice. FASEB. J., 21, 2149-2161.
38. Crawley, J.N., Belknap, J.K., Collins, A., Crabbe, J.C., Frankel, W., Henderson, N., Hitzemann, R.J., Maxson, S.C., Miner, L.L., Silva, A.J. et al. (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl), 132, 107-124.
39. Lucas, G.J., Daroszewska, A. and Ralston, S.H. (2006) Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders. J. Bone. Miner. Res., 21 (Suppl. 2), P31-P37.
40. Halawani, D. and Latterich, M. (2006) p97: The cell's molecular purgatory? Mol. Cell., 22, 713-717.
41. Dai, R.M., Chen, E., Longo, D.L., Gorbea, C.M. and Li, C.C. (1998) Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J. Biol. Chem., 273, 3562-3573.
42. Asai, T., Tomita, Y., Nakatsuka, S., Hoshida, Y., Myoui, A., Yoshikawa, H. and Aozasa, K. (2002) VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn. J. Cancer Res., 93, 296-304.
43. Vandermoere, F., El Yazidi-Belkoura, I., Slomianny, C., Demont, Y., Bidaux, G., Adriaenssens, E., Lemoine, J. and Hondermarck, H. (2006) The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J. Biol. Chem., 281, 14307-14313.
44. Soysa, N.S. and Alles, N. (2009) NF-kappaB functions in osteoclasts. Biochem. Biophys. Res. Commun., 378, 1-5.
45. Hiruma, Y., Kurihara, N., Subler, M.A., Zhou, H., Boykin, C.S., Zhang, H., Ishizuka, S., Dempster, D.W., Roodman, G.D. and Windle, J.J. (2008) A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum. Mol. Genet., 17, 3708-3719.
46. Najat, D., Garner, T., Hagen, T., Shaw, B., Sheppard, P.W., Falchetti, A., Marini, F., Brandi, M.L., Long, J.E., Cavey, J.R. et al. (2009) Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J. Bone Miner. Res., 24, 632-642.
47. Rea, S.L., Walsh, J.P., Ward, L., Magno, A.L., Ward, B.K., Shaw, B., Layfield, R., Kent, G.N., Xu, J. and Ratajczak, T. (2009) Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J. Bone Miner. Res., 24, 1216-1223.
48. Chamoux, E., Couture, J., Bisson, M., Morissette, J., Brown, J.P. and Roux, S. (2009) The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol. Endocrinol., 23, 1668-1680.
49. Peterson, J.M. and Guttridge, D.C. (2008) Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int. Rev. Immunol., 27, 375-387. Human Molecular Genetics, 2010, Vol. 19, No. 9 1755
50. Cai, D., Frantz, J.D., Tawa, N.E. Jr, Melendez, P.A., Oh, B.C., Lidov, H.G., Hasselgren, P.O., Frontera, W.R., Lee, J., Glass, D.J. et al. (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119, 285-298.
51. Salajegheh, M., Pinkus, J.L., Taylor, J.P., Amato, A.A., Nazareno, R., Baloh, R.H. and Greenberg, S.A. (2009) Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve, 40, 19-31.
52. Kusters, B., van Hoeve, B.J., Schelhaas, H.J., Ter Laak, H., van Engelen, B.G. and Lammens, M. (2009) TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta. Neuropathol., 117, 209-211
53. DeLaBarre, B. and Brunger, A.T. (2005) Nucleotide dependent motion and mechanism of action of p97/VCP. J. Mol. Biol., 347, 437-452.
54. Halawani, D., LeBlanc, A.C., Rouiller, I., Michnick, S.W., Servant, M.J. and Latterich, M. (2009) Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation. Mol. Cell. Biol., 29, 4484-4494.
55. Wu, C. and Ghosh, S. (1999) beta-TrCP mediates the signal-induced ubiquitination of IkappaBbeta. J. Biol. Chem., 274, 29591-29594.
56. Suzuki, H., Chiba, T., Kobayashi, M., Takeuchi, M., Suzuki, T., Ichiyama, A., Ikenoue, T., Omata, M., Furuichi, K. and Tanaka, K. (1999) IkappaBalpha ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, betaTrCP1 and betaTrCP2. Biochem. Biophys. Res. Commun., 256, 127-132.